Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients, this haematological malignancy remains incurable due to the development o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Melissa K., Li, Manjun, Tea, Melinda N., Pitman, Melissa R., Toubia, John, Wang, Paul P.-S., Anderson, Dovile, Creek, Darren J., Orlowski, Robert Z., Gliddon, Briony L., Powell, Jason A., Wallington-Beddoe, Craig T., Pitson, Stuart M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626806/
https://www.ncbi.nlm.nih.gov/pubmed/34826777
http://dx.doi.org/10.1016/j.neo.2021.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626806/
https://www.ncbi.nlm.nih.gov/pubmed/34826777
http://dx.doi.org/10.1016/j.neo.2021.11.009

Ejemplares similares